Verlyx Pharma Inc. is a privately-held pharmaceutical company involved in the development of liver-targeting therapeutic agents for the treatment of liver diseases. Verlyx’s lead product, VLX103, is a proprietary form of pentamidine that combines hepatoselective and hepatoprotective properties. Verlyx has initiated a purposeful clinical program based on VLX103, aiming at three important unmet needs in the field of liver diseases: NASH and ASH. Verlyx Pharma relies on accomplished individuals whose complementary expertise brings a high level of knowledge, innovation and management to the company. This team coordinates a network of collaborators and investigators dedicated to the success of the company and its products.
| Website | http://verlyx.com |
| Revenue | $2 million |
| Employees | 1 (0 on RocketReach) |
| Founded | 2000 |
| Address | 555 Boul Rene Levesque West, 9th floor, Montreal, Quebec H2Z 1B1, CA |
| Phone | +1 514-667-5081 |
| Technologies |
JavaScript
,
HTML
,
PHP
+20 more
(view full list)
|
| Industry | Biotechnology Research, Pharmaceuticals, Healthcare, Drug Manufacturing & Research, Biotechnology |
| Keywords | Pharmaceutical, Liver Disease Treatment, Pharma, Drug Development, Therapeutic Agents, Drug Discovery, Prescription Drugs, Drug Delivery, Research And Development, Biotechnology, New Drugs, Clinical Trials, Healthcare, Clinical Research |
| SIC | SIC Code 28 Companies, SIC Code 283 Companies |
| NAICS | NAICS Code 32 Companies, NAICS Code 3254 Companies, NAICS Code 32541 Companies, NAICS Code 325 Companies |
Looking for a particular Verlyx Pharma employee's phone or email?
Verlyx Pharma Questions
The Verlyx Pharma annual revenue was $2 million in 2026.
Verlyx Pharma is based in Montreal, Quebec.
The NAICS codes for Verlyx Pharma are [32, 3254, 32541, 325].
The SIC codes for Verlyx Pharma are [28, 283].
Related Companies
